Lab professionals share annual colorectal cancer test rates

April 9, 2026

Key Highlights

  • Colorectal cancer is the leading cause of cancer death among adults under 50 in the U.S.
  • Half of the patients under 50 were eligible for screening at diagnosis, highlighting missed opportunities for early detection.
  • A significant portion of labs process fewer than 100 tests annually, indicating potential limitations in screening capacity.
  • Early detection at a localized stage can lead to over 90% survival rates, emphasizing the importance of screening programs.

March was National Colorectal Cancer Month. Throughout March, Medical Laboratory Observer (MLO) asked readers to share how many colorectal cancer screening tests their labs process annually.

The American Cancer Society’s Colorectal Cancer Statistics, 2026 report revealed an alarming increase in colorectal cancer prevalence among younger adults. It is the top cause of cancer mortality for adults under 50 in the U.S., and the fourth most diagnosed cancer for all Americans. Additionally, half of colorectal cancer patients under 50 were eligible for screening at the time of diagnosis. UCDavis Health says “When colorectal cancer is caught early, at a localized stage, over 90% of patients survive.”

40% of respondents were unsure of how many colorectal cancer screening tests their labs processes. Additional key findings:

  • 28% of responding laboratorians reported that their labs process 100 or less colorectal cancer tests per year.
  • 8% said 101-500 tests.
  • 12% of responding labs said 501-1,000 tests are processed.
  • 12% reported more than 5,000 tests being processed by their labs annually.

Thank you to everyone who responded to our poll!

About the Author

Erin Brady

Managing Editor

Erin Brady is Managing Editor of Medical Laboratory Observer.

Sign up for our eNewsletters
Get the latest news and updates